Ellen Ruud

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · The Lancet Oncology · 2018 · 379 citations

Interleukin 2, Autoimmune Disease, Anti-gd2 Antibody Ch14.18/cho +7

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 334 citations · Full text

Oncology, Medicine, Versus Carboplatin +8

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · Cancers · 2020 · 139 citations · Full text

Excellent Outcome With Reduced Treatment for Infants With Disseminated Neuroblastoma Without <i>MYCN</i> Gene Amplification

Bruno De Bernardi, Mary Gerrard, Luca Boni et al. · Journal of Clinical Oncology · 2009 · 138 citations

Surgical Oncology, Pediatric Brain Tumors, Pathology +17

Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study

Ruth Ladenstein, Dominique Valteau‐Couanet, Penelope Brock et al. · Journal of Clinical Oncology · 2010 · 129 citations